Entyvio, the only Takeda drug tracked here, made ≈$6.0B of its 2025 revenue (21%) and loses US exclusivity in 2032. Since 2023, Takeda has closed 1 acquisition of $1B or more, worth $4.0B.
Bars are each drug's 2025 sales as a share of Takeda’s total revenue (≈$28.3B). Core revenue ¥4,505.7B, fiscal year to March 2026. Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Feb 2023 | Nimbus LakshmiTakeda, February 2023 | $4.0B | Immunology | Zasocitinib (TAK-279), an oral TYK2 inhibitor for psoriasis and other immune diseasesA Nimbus Therapeutics subsidiary; upfront payment, plus two $1B sales milestones. | Pipeline only |
| 1 counted | $4.0B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Takeda announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Immunology | ≈$6.0B | $4.0B |
Immunology is where Takeda has the most revenue at risk and where it has spent the most on acquisitions. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Takeda paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Takeda moved its assumption from May 2026 by three to five years, citing formulation, dosing and manufacturing patents. Pharma Japan
Revenue: Takeda FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Takeda’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →